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Bernheimer  and  Cantoni  (1),  in  1947,  described  an  unusual  "antitoxic" 
mechanism in mice, characterized by the development of a  temporary state of 
resistance  to the lethal effect of streptolysin O within hours of the intravenous 
administration  of sublethal  amounts of this toxin.  Rowen and Bemheimer  (2) 
subsequently  found  this  induced  refractoriness  to  be  associated  with  an  in- 
creased  capacity of plasma from the  treated  animals  to inhibit  the hemolytic 
action of the streptococcal toxin. The substance responsible for this inhibitory 
activity is not antibody, but has proved to be an unusual type of low density 
lipoprotein that is easily and quantitatively separable from the plasma by ultra- 
centrifugal flotation (3). In the course of efforts to immunologically characterize 
the  streptolysin  O  inhibitor  we have  uncovered  a  new  antigenic  component, 
distinct  from the  inhibitor,  in plasma  of mice  treated  with  the  streptococcal 
toxin. The new factor is not evoked exclusively by streptolysin O; it  also ap- 
pears  following exposure  of mice  to  certain  other  toxic materials  and  during 
acute bacterial infections.  The present  report  deals with  the  detection  of this 
new "acute phase" plasma component, the conditions under which it appears, 
and with experiments directed to its chemical and immunological characteriza- 
tion. 
Materials and Methods 
Streptolysin 0  Preparation.--The supematant fluid from a  15 liter  culture  of Group  A 
streptococcus, strain C203S, grown in a partially  defined medium (4), was fractionated  and 
concentrated  according to the procedure of Bemheimer and Cantoni (5). The product, cor- 
responding to the streptococcal preparation  A (SPA) of earlier reports  and assaying at  ap- 
proximately 50 mouse LD6o  per ml and 6000 hemolytic units  per ml (2), was stored at 4°C in 
0.8 saturated  ammonium sulfate. Prior to animal injection, the SPA was freed of ammonium 
sulfate by dialysis overnight  against  running  tap water,  activated for i0 minutes  at 20°C 
with an equal volume of 1 per cent cysteine hydrochlorlde at pH 7.0, and appropriately  diluted 
in 0.9 per cent NaCI. 
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Streptolysin 0  Inhibitory Mouse Plasma.--White mice of the Webster strain  (Carworth 
Farms  New  City,  New  York),  weighing  16  to  20  gm,  were  used  exclusively.  Unless 
otherwise indicated, animals received 2 intravenous injections of the toxin preparation: the 
first was equivalent to ~  of an LDs0 while the second, given 16 to 20 hours later, consisted 
of one LDs0.  Mice under ether anesthesia were bled from the heart approximately 20 hours 
after the second injection. Coagulation was prevented by rinsing the syringe with 2 per cent 
heparin in saline and special precautions (2) were taken to avoid hemolysis. In experiments 
involving pooled plasma each pool was obtained from 50 to 75 mice. Since treatment with 
streptolysin O renders the mice refractory to the lethal effect of the toxin, plasma from such 
mice is referred to as refractory mouse plasma (RMP), as distinguished from plasma of un- 
treated mice (NMP). All plasma samples were stored at --20°C until use. 
Antisera.--Anti-RMP was prepared by immunization of a rabbit with intact pooled RMP. 
After an initial intraperitoneal injection of 0.5 ml of the plasma, the animal was given 4 in- 
travenous injections (0.5 to 1.0 ml each) per week, on successive days, for 8 weeks. Bleedings 
were made 9, 10, and 11 weeks after the start of immunization. Between bleedings the rabbit 
was given one intravenous injection of 0.5 ml of RMP and allowed to rest for 6 days. 
To render the antiserum specific for components peculiar to RMP, the anti-RMP was ab- 
sorbed 3 times with 0.1 volume of pooled NMP. After each addition of NMP the mixture was 
placed at 4°C for 48 hours then centrifuged to remove any precipitated material. Three ab- 
sorptions were usually sufficient to deplete the antiserum of antibodies to all normal antigenic 
plasma components. However, when absorptions were carried out with certain lots of NMP 
that had been stored for several months, the absorbed anti-RMP retained some precipitating 
antibody for/3-1ipoprotein. 
Sheep antiserum to C-reactive protein (CRP) was a product of Schieffelin and Company, 
New York City. Horse anti-CRP, as well as horse and goat anti-CxRP, were purchased from 
Hyland Laboratories, Los Angeles. 
Immunodiffusion and Immunodectrophoresis.--Double diffusion in agar by the Ouchterlony 
technique  (6) was carried  out  on  3~  X  4 inch lantern slides using a  gel composed of  1 
per cent Noble agar (Difco Laboratories, Detroit) in veronal buffer (pH 8.6, ionic strength 
0.025) containing 1 : 10,000 merthiolate. Patterns were allowed to develop in a moist chamber 
for 2 days at room temperature or for 3 to 4 days at 4°C. The plates were then washed over a 
period of a week with several changes of phosphate-buffered  saline at pH 7.0 and dried. Slides 
were stained for protein with naphthol-blue-black, for lipoprotein with a saturated solution 
of oil red O in 60 per cent ethanol, or for bound hemoglobin with a benzidine-peroxide  reagent 
(7). 
The micromethod of Scheidegger (8)  was employed for immunoelectrophoretlc analysis. 
The gel was of the same composition as that used for simple immunodiffusion. Patterns were 
allowed to develop for 3 to 4 days at 4°C and then treated as described above. 
Plasma Fractionations.--Streptolysin  0  inhibitor was separated from RMP by ultracen- 
trifugal flotation, as previously reported (3). 
Starch block electrophoresis was carried out according to the technique of Kunkel and 
Slater (9) with slight modification. Separations were made on a 37.5  X  10 X  1.5 cm starch 
block using veronal buffer at pH 8.6 and ionic strength 0.075.  Six ml of RMP was concen- 
trated to 2 ml by dialysis against 20 per cent polyvinylpyrrolidone (PVP) in veronal buffer 
before application to the block. Following electrophoresis  for 42 hours at 4°C using a constant 
current of 50 ma, the block was cut into 1 cm segments and the plasma components in each 
segment recovered with the aid of a flitted glass filter by 2 separate washings with 3 ml saline. 
Protein in the eluate of each segment was determined by a  modification of the Lowry pro- 
cedure using the Folin-Ciocalteu phenol reagent  (10).  Relative distribution of hemoglobin 
added to the plasma prior to electrophoresis was ascertained by measuring the absorbance at 
410 m# (11) of each fluid fraction. "Spot" tests of the various fractions were carried out on 
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diffuse  into the agar,  and  the slides  then exposed  to the appropriate  reagents.  Lipids were 
detected with oil red  O.  The presence of ceruloplasmin  and  carbohydrate  was  determined 
by procedures outlined by Uriel (12). The method of Nachlas and Seligman (13) was used to 
test for/~-naphthyl acetate esterase activity. 
Toxic Preparations other than Streptolysin O.--The saponin used  (Lot NM,  Coleman and 
Bell Company, Norwood, Ohio) was of undefined purity. Crotalus adamanteus venom (phos- 
pholipase A)  was  a  lyophilized sample  obtained  from  Ross Allen Reptile  Institute,  Silver 
Springs, Florida.  Partially purified Clostridium welchii phospholipase C was purchased from 
Worthington Biochemical Corporation,  Freehold, N. J. Lipopolysaccharide endotoxins were 
from Difco Laboratories.  Staphylococcal a-toxin was kindly provided by Dr. Alan W. Bern- 
helmet; it was estimated to be 70 per cent pure and to contain approximately 15 hemolysin 
units per #g protein (14). 
Bacterial Cultures.--All  organisms tested for their capacity to elicit the abnormal protein 
were grown overnight at 37°C in heart infusion broth containing 5 per cent horse serum. Ani- 
mals received 0.1  ml of the  freshly grown culture,  injected intraperltoneally. 
FIGS.  1 a  and  1 b.  Demonstration by immunodiffusion of abnormal antigen in plasma of 
streptolysin 0-treated  mice.  In Fig.  1 a individual  pools of NMP and  RMP were diffused 
against  rabbit  antiserum  to  RMP;  reactions  of non-identity  are  indicated  by  the  arrows. 
Fig. 1 b shows the same plasma samples diffused  against anti-RMP that had been absorbed 
with NMP. 
EXPERIMENTAL 
Demonstration of a New Antigenic Component in Plasma of Mice Treated with 
Streptolysin  O.--In  an  attempt  to  determine  the  relationship  between  the  in- 
duced  streptolysin  O  inhibitor  and  normal  plasma  lipoproteins,  various  pools 
of NMP  and  RMP  were examined  by immunodiffusion  in agar using  an  anti- 
serum prepared against intact RMP.  Typical of the patterns  that were obtained 
are those shown in Fig.  1 a.  It may be seen that each pool of RMP  contains  at 
least one antigenic component that fails to give a  reaction of identity with any 550  ACUTE  PHASE  PROTEIN  IN  MOUSE  PLASMA 
of the  reactive components in NMP.  The presence  of an  antigen peculiar  to 
RMP was verified by absorbing the anti-RMP with NMP and then diffusing the 
absorbed antiserum  against the same samples of plasma. When this was done 
(Fig. 1 b), no precipitation occurred between NMP and the absorbed antiserum, 
while each pool of RMP yielded a distinct band of precipitate. 
Using the absorbed antiserum, plasma samples of individual normal mice and 
mice treated with either one or two injections of streptolysin O were tested by 
agar diffusion for presence of the abnormal antigen. The results are summarized 
in Table I. As expected, none of the normal plasma samples reacted with the 
absorbed antiserum, while  over 70 per cent of the mice treated with the usual 
course of 2 injections of the toxin had the antigen present in their plasmas. A1- 
TABLE I 
Induced Appearance of Abnormal Plasma Component in Individual Mice Treated with SPA 
Group  Treatment of mice prior to bleeding 
Untreated 
I! One i.v. injection SPA: 1~ of an LDs0 
Two i.v. injections SPA: 1~ of an LD50 
i  followed  at 24 hours by one LDs0 
~TO, of 
mice 
16 
5 
25 
I 
No. showing 
abnormal 
antigen in 
plasma* 
0 
4 
18 
* Treated mice were bled 18 to 20 hours after final injection of toxin and the plasma tested 
by immunodiffusion in agar vs. absorbed anti-RMP. 
though most of the RMP used in the experiments to follow were obtained from 
mice that had received 2 injections of streptolysin O, Table I reveals that even 
a  single  injection comprising 1/~ of an LDs0 was sufficient  to cause the appear- 
ance of the abnormal plasma component in the majority of the animals tested. 
The short delay in appearance and the transitory nature of the abnormal com- 
ponent is suggested by the results  of an experiment in which individual mice 
were bled at various intervals after a single injection of t/~ of an LD~o SPA, and 
each plasma sample tested separately by immunodiffusion with absorbed anti- 
serum for the presence of the abnormal component. As indicated  in Table II, 
the component was not detected in plasma of mice bled 1, 3, or 6 hours following 
toxin, but was detected in 2 of the 3 mice sampled at 24 hours. Plasma obtained 
48 hours after toxin administration failed to react with the absorbed antiserum. 
Characteristics of the New Componenl.--The immunoelectrophoretic patterns 
of RMP and NMP, developed with both absorbed and unabsorbed anti-RMP, 
are compared in Fig.  2. Although the new factor is not readily apparent in the 
pattern of RMP obtained with unabsorbed antiserum, it is strikingly revealed 
when the antiserum is first absorbed with NMP. The new component migrates ROBERT  ROWEN  AND  MYRTLE  A.  WIEST  551 
in the agar as an a2-globulin and shows no tendency to bind lipid stain. By its 
failure to take the lipid stain and by a difference in electrophoretic mobility, 
the new component is easily distinguished from low density lipoprotein which is 
augmented following exposure of mice to streptolysin O (3). 
TABLE  II 
Appearance of Abnormal Antigen in Mouse Plasma as a Function of Time after Administration 
of a Single Dose of SPA 
Time after i.v. injection of ~  of  No. showing  abnormal antigen  an LD~0 SPA  No. of mice tested  in plasma 
hrs. 
1 
3 
6 
24 
48 
FIO.  2.  Immunoelectrophoretic patterns of refractory mouse plasma  (RMP)  and  normal 
mouse plasma (NMP)  developed with unabsorbed and absorbed anti-RMP.  Duplicate slides 
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That  the new component is  distinct from the streptolysin O inhibitor  was 
firmly  established  by  separating  the  inhibitor  from  the  rest  of  the  plasma 
through ultracentrifugal flotation and  then testing each fraction by immuno- 
diffusion for the presence of the abnormal component. When this procedure was 
carried out with NMP and RMP, the new antigenic component was found only 
in the inhibitor-free residual fraction (RF) of RMP (Fig. 3). The band of pre- 
FIG. 3. Immunodiffusion  analysis with absorbed anti-RMP of ultracentrifugally-derived 
fractions of NMP and RMP. FF is the floatable fraction of the plasma having a density of less 
than  1.006 and containing the streptolysin O inhibitor. RF, the residual fraction, represents 
the remainder of the plasma. Slide has been stained for protein. Band of precipitate repre- 
senting abnormal component in RF of RMP is indicated by the arrow; all bands but this show 
affinity for lipid stain. 
cipitate did not stain with oil red O, while  a  band that appeared with the in- 
hibitor-rich floatable fraction (FF)  of the  same RMP  took the stain heavily. 
Since the antiserum used to develop the patterns of Fig. 3 was, for illustrative 
purposes, incompletely absorbed,  a  band of precipitate  was also formed with 
normally-occurring lipoprotein present in the residual fractions of both NMP 
and RMP. This band is closer to the antigen well than that produced by the ab- 
normal component and is easily distinguished from the latter by its ability to 
take the lipid stain. 
The possibility that the abnormal component might represent unconsumed 
streptolysin  O in  the  blood of the  treated  animals  seemed unlikely since  the 
component was not detected in plasma during the first few hours after toxin ad- ROBERT  ROWEN  AND  MYRTLE  A.  WIEST  553 
ministration (see Table II). Further differentiation was provided by the failure 
of samples of pooled human 3,-globulin,  which were able to precipitate with the 
streptolysin O preparation used for injection of the mice,  to show a  reaction 
with  RMP;  likewise,  by  the  lack  of  reaction  between  anti-RMP  and 
SPA. Finally, as will be described, the abnormal component' may be elicited by 
agents entirely unrelated to streptolysin O. 
Considering that the new component might be a form of C-reactive protein, 
attempts were made to demonstrate interaction between RMP and a purified 
preparation of pneumococcal C polysaccharide, kindly supplied by Dr. Michael 
FIG. 4. Immunodiffusion  tests of RMP and human CRP-positive serum before and after 
absorption with pneumococci. A, untreated RMP or human CRPq- serum; B, same plasma 
and serum absorbed with Type 1 pneumococcus;  and C, same absorbed with Type 2 pneumo- 
coccus. Trough of upper slide contained rabbit anti-RMP absorbed with NMP. Trough of 
lower slide contained sheep antl-human CRP. 
Heidelberger. Using a ring test in narrow test tubes in the presence of calcium 
ions, we were unable to detect any precipitation with the polysaccharide in con- 
centrations from 4 to 400/zg per ml, even after storage in the cold for 5 days. 
Human acute phase  serum,  used  as  a  control, clearly reacted with  the poly- 
saccharide  over  this  same  range  of concentrations.  In  another  approach,  an 
effort was made to remove the abnormal component from RMP by repeated 
exposure to intact Type 1 and Type 2 pneumococci. As shown in Fig. 4,  the 
treatment was entirely ineffective with RMP but removed virtually all of the 
CRP from a  sample of human acute phase serum.  Fig. 4 also shows that ab- 
sorbed anti-RMP does not react with CRP-positive serum and that sheep anti- 
CRP, which is known to cross-react with monkey and rabbit acute phase pro- 
tein (15), fails to form a precipitate with RMP. Although not illustrated, horse 
anti-CRP and horse or goat anti-CxRP (16) also had no effect on RMP. 554  ACUTE  PHASE  PROTEIN  IN  MOUSE  PLASMA 
Since elevations in serum haptoglobin are known to occur during acute patho- 
logical  states  (17, 18),  and  since  haptoglobin migrates  as  an ol2-globulin  on 
electrophoresis, it seemed important to test  the capacity of the new factor in 
RMP to bind hemoglobin. Various samples of NMP and RMP to which 0.05 
volume of a  1:4 mouse erythrocyte lysate (18) had been added were subjected 
to  immunoelectrophoresis  using  absorbed  anti-RMP.  After  several  days  of 
diffusion at 4°C, the slides were washed and stained for hemoglobin with benzi- 
dine-peroxide reagent. No accumulation of hemoglobin was detected in the band 
of  precipitate  representing  the  abnormal  component.  When  the  slides  were 
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FIG. 5. Distribution of protein, hemoglobin, and abnormal antigen following starch block 
electrophoresis of pooled RMP containing a small amount of added hemoglobin. Origin is 
indicated by the arrow. Protein was measured with the Folin-Ciocalteu phenol reagent and is 
recorded as absorbance at 650 m#. Hemoglobin is measured as direct absorbance at 410 m/~. 
Localization of the abnormal component was accomplished by immunodiffusion tests with 
absorbed anti-RMP. 
stained  for hemoglobin without prior  washing,  a  higher proportion of hemo- 
globin in the region of (~2-globulin  was found in the RMP than in the NMP; 
however, this apparently bound hemoglobin migrated slightly ahead of the ab- 
normal component. 
Analyses  of Eleclrophoretic Fractions of RMP.--Further information regard- 
ing the nature of the abnormal antigen and its relationship to other plasma con- 
stituents was obtained by starch block electrophoresis of hemoglobin-enriched 
RMP  and  subsequent  examination  of  the  derived  fractions.  Each  fraction, 
eluted from consecutive 1 cm segments of the starch block, was analyzed for 
protein  and  hemoglobin content  and  subjected  to  agar  diffusion against  ab- 
sorbed anti-RMP to localize  the abnormal component. As indicated in Fig. 5, 
the latter was limited to fractions 14,  15, and 16 located at the trailing edge of 
the o~2-globulin. Fraction 15, which seemed to have the greatest concentration ROBERT  ROWEN  AND  MYRTLE  A.  WIEST  555 
of the abnormal antigen, contained a little over 1.5 per cent of the total protein 
recovered from the block. Immunoelectrophoresis with unabsorbed antiserum 
of the 3 fractions containing the abnormal antigen (Fig. 6) indicated that,  al- 
though considerable purification had been achieved, each contained 1 or 2 nor- 
mal plasma components with approximately the same electrophoretic mobility 
as the streptolysin O-induced antigen. The previous failure to demonstrate any 
relationship between the abnormal component and plasma haptoglobin is con- 
Fro. 6. Immunoelectrophoretic analysis of starch block fractions containing the abnormal 
antigen (see  Fig.  5).  Patterns were developed with unabsorbed anti-RMP.  Abnormal com- 
ponent (indicated by arrows) was identified by comparison with second set of slides developed 
with absorbed anti-RMP. 
sistent  with  the  observed  distribution  of hemoglobin following starch  block 
electrophoresis as expressed in Fig. 5. Thus, the peak localizations of hemoglobin 
do not coincide with that of the abnormal antigen. Haptoglobin is probably rep- 
resented by the bound hemoglobin distributed between fractions 16 to 20, while 
free hemoglobin is that seen in the region of the ~-globulin (18). 
In addition to measurement of protein and hemoglobin, "spot" tests for lipid, 
ceruloplasmin, ~-naphthyl acetate esterase, and carbohydrate were carried out 
on the individual fractions from the starch block. The results obtained for frac- 
tions 9 to 20 are given in Table III. No ceruloplasmin and no more than a trace 
of lipid were detected in the 3 fractions containing the abnormal antigen. Some 
carbohydrate was revealed in fraction 16 but was either absent or present in 
trace amount in the two other fractions containing greater concentrations of the 556  ACUTE  PHASE  PROTEIN  IN  MOUSE  PLASMA 
abnormal component.  Appreciable esterase  activity was  found  in fraction  14 
but was progressively less in the next two fractions. There is thus no evidence 
that lipid, carbohydrate, or esterase activity is directly associated with the ab- 
normal antigen, although further study will be needed before a firm conclusion 
can be reached. The results of tests for ceruloplasmin must be considered incon- 
clusive as no more than  a  trace of activity was detected in the intact plasma. 
Since the presence of ceruloplasmin was judged on the basis of oxidase activity, 
it is possible that none was found because the enzyme had undergone inactiva- 
tion during storage of the plasma. If ceruloplasmin is a  normal antigenic corn- 
TABLE III 
Spot Test Analyses of Fractions Derived from RMP by Starch Block Electrophoresis* 
Fraction  Carbohydrate  Lipid  /~-naphthyl  p-phenylenediamineoxidase 
acetate esterase  ("ceruloplasmin") 
9 
lO 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Intact plasma 
+ 
+++ 
++ 
++ 
4- 
0 
-4- 
+ 
++ 
++ 
+++ 
+++ 
++++ 
0 
o 
0 
0 
0 
0 
4- 
=t:: 
+ 
o 
+ 
++ 
++++ 
0 
0 
0 
4- 
+ 
++ 
+ 
4- 
o 
0 
o 
0 
++++ 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Trace 
*Refer to Fig. 5. 
ponent of mouse plasma  I, as it is in human serum, antibody specific for  it pre- 
sumably would have been removed during absorption of the anti-RMP. 
The protein nature of the abnormal component was firmly established by in- 
vestigating the action of proteolytic enzymes on the partially purified material 
derived by starch block electrophoresis. Thus,  after treatment of the eluate of 
segment 15 with either trypsin (Fig. 7) or papain (Fig. 8) the abnormal antigen 
could no longer be demonstrated with absorbed antiserum.  Conditions in these 
1 Clausen  and Heremans  (19), using the p-phenylenediamine  staining procedure,  found, 
after electrophoresls  of mouse serum in agar, a small amount of oxidase activity in a region 
between  the fast fl- and slow s-globulins. They made particular mention of the fact that 
"ceruloplasmin" in mouse serum has much weaker staining properties than the comparable 
human protein. In a survey conducted by Seal (20), using oxidation of p-phenylenedlamine 
in the test tube as the assay method, it was estimated that mouse serum had less than half 
the "ceruloplasmin" activity of human serum. ROBERT ROWEN AND MYRTLE A.  WIEST  557 
experiments were such as to eliminate the possibility of destruction of the de- 
tecting antibody by residual enzyme in the incubation mixtures. In the case of 
trypsin,  sufficient  soy  bean  trypsin  inhibitor  was  added  to  the  incubation 
mixture  before  diffusion  to completely arrest  proteolytic  action.  Papain,  by 
virtue of its relatively high isoelectric point, was separated from the abnormal 
component during immunoelectrophoresis which was used to evaluate the effect 
of the latter enzyme. 
FIG. 7. Ouchterlony plate showing the effect of trypsin on the capacity of the abnorma 
component in RMP to precipitate with specific antibody. A, untreated fraction 15 of Fig. 5; 
B, same fraction incubated with 0.0125 per cent trypsin for 3 hours at 37°C; C, fraction 15 
incubated with enzyme diluent (phosphate buffer, pH 7.0) for 3 hours at 37°C; and D, frac- 
tion 15 incubated 3 hours at 37°C with 0.0125 per cent trypsin, followed by addition of soy 
bean trypsin inhibitor to a final concentration of 0.0125 per cent. Center well contained anti- 
RMP absorbed with NMP. 
Capacity of Agents other than Streptolysin 0 to Elicit the Abnormal Plasma Com- 
ponent.--The  induced  appearance  of  the  abnormal  antigen  is  not  a  unique 
manifestation of streptolysin 0  intoxication. Thus, following parenteral admin- 
istration of a variety of toxic materials (Table IV), and during acute  bacterial 
infections (Table V), there is present in mouse plasma a component that reacts 
with absorbed anti-RMP. Immunoelectrophoresis and simple immunodiffusion 
tests verify that this component is identical to that evoked by streptolysin O. A 
typical demonstration of immunological identity with several of the test plasmas 
is shown in Fig. 9. 
Finding that the abnormal protein could be elicited by saponin was not en- 
tirely unexpected.  Saponin, like streptolysin O, is  lethal  for mice, hemolytic, 558  ACUTE  PHASE  PROTEIN  IN  MOUSE  PLASMA 
and inhibited by relatively minute amounts of cholesterol (21). However, there 
is little to relate the other effective toxins (i.e. phospholipase C and endotoxins) 
to streptolysin O. Saponin stands apart from the other effective preparations in 
that  two doses were required  to elicit the  abnormal protein.  The inability of 
snake venom phospholipase A and staphylococcal a-toxin to evoke the abnor- 
mal protein may either be a function of the dosage schedules employed or a re- 
flection of some important difference in the physiological response of the host 
to these toxic materials as compared to the others that were tested. 
FIG. 8. Effect of papain on immunological reactivity of the abnormal component in RMP. 
Slide A  shows the results of immunoelectrophoresis after incubation of the partially purified 
acute phase component (fraction 15 of Fig. 5) for 2 hours at 37°C with enzyme diluent (upper 
well) and with 0.005 per cent papain (lower well). Slide B shows a 1 per cent solution of papain 
electrophoresed concurrently with slide A  and stained directly for protein.  (Enzyme diluent 
contained  1 )<  10  -8 ~t EDTA,  5 >(  10  -a ~t  cysteine, and  3 X  10  --5 •  2,  3,  dimercapto-1- 
propanol.) 
The  appearance  of  the  abnormal  protein  during  acute  infection  with  the 
C203S strain of Group A streptococci could conceivably be attributed to in vivo 
production of streptolysin O, and, in the case of pneumococci, to the release of 
pneumolysin,  an oxygen-labile toxin closely related to streptolysin O  (22,  23). 
Yet, this need not be the case, since the protein also appears in plasma of mice 
infected with staphylococci and with the Blackmore strain of Group A strepto- 
coccus, a variant apparently lacking the capacity to produce streptolysin O (24). 
It seems evident from these experiments that the newly discovered component 
in  RMP  is an acute phase protein produced or released in vivo under various 
conditions  of  toxic  or  infectious  stress.  No  doubt  a  multitude  of  deleterious 
agents, other than those presently described, are capable of eliciting the factor. 
Preliminary Experiments Relating to the Source of the Induced A ntigen.--In an ROBERT  ROWEN  AND  MYRTLE  A.  WIEST  559 
TABLE  IV 
Elicitation  of Abnormal  Antigen by Toxic Materials  other than Streptolysin  0 
Preparation 
S. typhosa  lipopolysaccharide 
(endotoxin) 
E. coli lipopolysaccharide 
(endotoxin) 
Cl. welchii a-toxin (phospho- 
lipase C) 
Saponin 
Staphylococcal a-toxin 
Approximate 
lethal dose* 
~g 
75O 
Not tested 
I0 
500 
Dose 
administercd$ 
~g 
100 
Crotalus adamanteus  venom 
(phospholipase A) 
Crotalus adamanteus  venom 
(phospholipase A) 
1.5  (protein) 
100 
100 
125  +  500 (2 
injections) 
0.4 
0.4 +  1.6 (2 
injections) 
40  10 
10 +  40 (2 
injections) 
No. of 
mice 
No. showing 
abnormal antigen 
in plasma 
0 
0  (of  3  sur- 
vivors) 
* Amount necessary to kill 50 per cent or more of normal mice in 24 hours. 
:~ Where 2 injections were given they were separated by an interval of 24 hours. Mice were 
in all cases bled 16 to  18 hours after the last injection. 
TABLE  V 
Presence  of Abnormal  Component  in Plasma of Mice during  Acute  Bacterial  Infections 
Infecting agent 
None, sterile culture medium 
Streptococcus pyogenes, strain 
C203S  (Type 3) 
Streptococcus pyogenes,  Blackmore 
strain (Type 12) 
Diplococcus pneumoniae,  (Type 1) 
Staphylococcus  aureus,  strain F10 
Characteristics of infecting agent 
Smooth variant used in prepa- 
ration of SPA 
Variant lacking capacity to 
produce streptolysin O 
Smooth, mouse passed stock 
strain 
Coagulase positive stock strain 
No. showing 
Nine  of  abnormal 
antigen in 
plasma 
* Mice were given 0.1  ml of overnight broth culture intraperitoneally  18 hours prior to 
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attempt to learn the source of the acute phase plasma component, efforts were 
made to extract the factor from heart, liver, lung, spleen, kidney,  and skeletal 
muscle  of normal mice.  Homogenates of these  organs were  subjected  to both 
sonic disruption and incubation for 1 hour at 37°C with reduced SPA. In neither 
instance was the antigen detected in the supernatant  fluid after centrifugation 
of the test preparation.  Tests for the antigen in particulate  fractions of tissue 
homogenates are presently being carried out. 
FIG. 9.  Immunodiffusion pattern  showing reactions  of identity  between  abnormal  com- 
ponent in RMP and  that  appearing  in plasma  of mice treated  with  other agents.  M-P-A, 
plasma of mice infected with Group A streptococcus, strain  C203S; MP-B, plasma of mice 
infected with Type 1 pneumococcus; MP-C, plasma of mice given 2 intravenous injections of 
saponin (see Table IV) ; NMP, pooled plasma of normal mice. Center well contained anti-RMP 
absorbed with NMP. 
Considering the possibility that the antigen may have been derived from one 
or more of the formed elements of the blood, freshly drawn heparinized mouse 
blood was incubated for 6 hours at 37°C with various concentrations of reduced 
SPA. Plasma was then separated from each incubation mixture by centrifuga- 
tion and tested for the presence of the abnormal antigen. Results were uniformly 
negative. 
A possible relationship between the induced protein and a surface component 
of mouse erythrocytes was suggested by the chance observation that our prepa- 
ration of absorbed anti-RMP had a remarkable capacity to agglutinate washed 
mouse  red  cells  from  normal  animals.  (Anti-NMP  also  agglutinated  the  red 
cells,  but  to  a  lesser  extent.)  However,  repeated  absorption  of the  antiserum 
with washed red cells failed to diminish its capacity to react with the abnormal ROBERT  ROWEN  AND  MYRTLE  A.  WIEST  561 
antigen.  Although experiments are continuing,  the source of the acute phase 
protein remains obscure. 
DISCUSSION 
Prior studies  (2, 3) have established that  treatment  of mice with  suitable 
doses of streptolysin O is followed by the appearance in the plasma of a low den- 
sity lipoprotein inhibitory to the streptococcal toxin, as well as by a generalized 
increase in all classes of plasma lipoproteins.  These changes are now shown to be 
accompanied by introduction into the plasma of a new and immunologically dis- 
tinct protein component. It is tempting to speculate that production of this ab- 
normal component and of the streptolysin O inhibitor are manifestations of a 
single process, considered not as a unique response to streptolysin O but as a 
type of physiological reaction to a variety of noxious agents. Thus, mice treated 
with sublethal doses of saponin show the newly distinguished plasma protein 
(Table IV, Fig. 9), exhibit resistance to the lethal activities of saponin and of 
streptolysin O (1) and have present in their plasma a low density lipoproteinin- 
hibitory to both toxic materials (25). Experiments are in progress to determine 
whether other deleterious agents with capacity to elicit the presently described 
abnormal protein (e.g.  endotoxins,  phospholipase C, and pathogenic bacteria) 
are also able to stimulate the production of streptolysin O inhibitory lipoprotein. 
It would also be interesting to know what relationship exists between the ap- 
pearance of the abnormal protein following endotoxin administration and such 
well known biological  effects of endotoxins as fever, Schwartzman reactivity, 
leukocytic alterations, increase in non-specific resistance to bacterial infections, 
and the production of shock (26). 
Williams and Wemyss (18) have demonstrated that immunoelectrophoretic 
patterns of mouse plasma proteins are significantly  altered during acute infec- 
tions and upon exposure of mice to endotoxins;  among  the more prominent 
changes is a marked elevation of haptoglobin migrating in the region  of a2- 
globulin.  Present  experiments  reveal  increased  amounts  of  haptoglobin  in 
plasma of mice treated with streptolysin O, but also indicate that no relationship 
exists between the haptoglobin and the newly described acute phase protein; for 
example,  the latter  fails  to bind hemoglobin  and~ migrates  independently  of 
haptoglobin upon electrophoresis. 
The acute phase protein induced in mice is clearly distinct from C-reactive 
protein in its immunological specificity and in its failure to precipitate with 
pneumococcal C polysaccharide. It bears some resemblance to C-reactive pro- 
tein of man and of monkey (27) and to the Cx-reactive protein of rabbits (16) 
with respect to the type of eliciting  agents, its relatively rapid appearance fol- 
lowing  exposure to these agents,  and in its transitory nature. The abnormal 
protein appearing in rat serum following administration of endotoxins and other 
cytotoxic agents (28) may be another example of an acute phase protein lacking 562  ACUTE  PHASE  PROTEIN  IN  MOUSE  PLASMA 
the configuration necessary for combination with pneumococcal C polysaccha- 
ride and for the serological  specificity shared by C- and Cx-reacfive proteins. 
Such protein~ may be produced by many animal species  but their detection 
may require special techniques such as the use of appropriately absorbed anti- 
serum as in the present work. 
Perhaps related to our findings is the recent observation that certain bacteria 
or bacterial endotoxins, when injected into mice (29) or rabbits (30), cause the 
temporary appearance in the serum of a viral inhibitor tentatively classified as 
interferon. The possibility that this viral inhibitor and the newly described acute 
phase protein have a common origin, or may in fact be identical, is worth serious 
consideration. 
SUMMARY 
A new acute phase plasma component has been found in mice exposed to cer- 
tain toxic materials and pathogenic bacteria. The abnormal component, detected 
by  immunodiffusion employing absorbed  antiserum,  was  chiefly studied  in 
plasma of streptolysin O-treated mice where it appears within 24 hours after 
intravenous administration of a sublethal dose of the toxin. The new factor is a 
protein having the electrophoretic mobility of a slow a2-globulin. It is devoid of 
lipid and separate from the streptolysin O inhibitory lipoprotein that is also in- 
duced by administration of the streptococcal toxin. The factor, moreover, ap- 
pears clearly distinct from haptoglobin or C-reactive protein and seems to be a 
unique  type of acute phase protein.  Its  partial purification by starch  block 
electrophoresis is described. 
A number of toxic materials other than streptolysin O, i.e. saponin, Cl. welchii 
phospholipase C  (a-toxin), and endotoxins, were found to elicit the abnormal 
protein in mice. Phospholipase A (Crotalus adamanteus venom) and staphylococ- 
cal a-toxin failed to cause its appearance. Plasma samples of mice acutely in- 
fected with Group A streptococci, Staphylococcus  aureus or pneumococcus uni- 
formly contained the abnormal component. 
The significance of this acute phase protein has been considered in relation to 
the streptolysin O inhibitor and to the acute phase proteins of other animal 
species.  It has been suggested that production of the new component and of the 
streptolysin O inhibitor may be manifestations of a single process constituting 
a physiological response to a variety of deleterious agents. 
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